secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2026-08-07T11:03:03+00:00
Accession:  0001372514-26-000075
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora Q2 2026 net loss $2.1M; cash $16.8M; ABACUS-2 higher-dose enrollment underway
--------------------------------------------------------------------------------

- Net loss $2.1M vs $2.2M YoY; R&D expense $2.1M net of $1.3M Théa reimbursement; G&A flat at $1.4M.
- Cash and short-term investments $16.8M at June 30, up from $13.9M at March 31; runway into late 2028.
- Private placement secured for up to $24M gross, $5M upfront, remainder contingent on milestone-based warrant exercise.
- ABACUS-2 Phase 2 (KIO-301) enrolling higher 100 µg dose cohort; last patient first visit Q1 2027, topline Q3 2027.
- KIO-104 KLARITY Phase 2 enrolling higher-dose cohort; initial clinical data expected late 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000137251426000075/0001372514-26-000075-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000137251426000075/kprx-20260807.htm
  HTML page:      https://secwatch.observer/filing/0001372514-26-000075

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer